首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   168篇
  免费   3篇
  国内免费   1篇
耳鼻咽喉   3篇
儿科学   3篇
妇产科学   4篇
基础医学   11篇
临床医学   13篇
内科学   13篇
皮肤病学   2篇
神经病学   5篇
特种医学   7篇
外科学   56篇
综合类   15篇
预防医学   5篇
眼科学   6篇
药学   12篇
  1篇
中国医学   7篇
肿瘤学   9篇
  2023年   3篇
  2022年   2篇
  2021年   1篇
  2020年   2篇
  2019年   21篇
  2018年   21篇
  2017年   7篇
  2016年   1篇
  2015年   3篇
  2014年   2篇
  2013年   2篇
  2012年   3篇
  2011年   4篇
  2010年   3篇
  2009年   5篇
  2008年   11篇
  2007年   7篇
  2006年   7篇
  2005年   6篇
  2004年   10篇
  2003年   5篇
  2002年   3篇
  2001年   3篇
  2000年   1篇
  1999年   6篇
  1998年   4篇
  1997年   3篇
  1996年   3篇
  1995年   1篇
  1992年   1篇
  1990年   1篇
  1985年   1篇
  1984年   5篇
  1983年   2篇
  1982年   4篇
  1981年   1篇
  1980年   2篇
  1979年   1篇
  1978年   1篇
  1975年   2篇
  1974年   1篇
排序方式: 共有172条查询结果,搜索用时 15 毫秒
1.
2.
3.
目的 分离鉴定青叶胆 Swertia mileensis全草的酮类成分。方法  95 %乙醇浸提 ,经硅胶柱色谱分离纯化 ,UV,IR,MS,1 H和 1 3CNMR波谱方法确定化学结构。结果 分得 12个酮成分 ,分别为 1-羟基 - 2 ,3,4 ,5 -四甲氧基酮 (1- hydroxy- 2 ,3,4 ,5 - tetramethoxyxanthone, ) ;1-羟基 - 2 ,3,7-三甲氧基酮 (1- hydroxy- 2 ,3,7-trim ethoxyxanthone, ) ;1-羟基 - 2 ,3,5 ,7-四甲氧基酮 (1- hydroxy- 2 ,3,5 ,7- tetram ethoxyxanthone, ) ;1,5 -二羟基 - 2 ,3-二甲氧基酮 (1,5 - dihydroxy- 2 ,3- dimethoxyxanthone, ) ;1,5 -二羟基 - 2 ,3,7-三甲氧基酮 (1,5 - dihy-droxy- 2 ,3,7- trimethoxyxanthone, ) ;1-羟基 - 2 ,3,5 -三甲氧基酮 (1- hydroxy- 2 ,3,5 - trimethoxyxanthone, ) ;1,5 -二羟基 - 2 ,3,4 ,7-四甲氧基酮 (1,5 - dihydroxy- 2 ,3,4 ,7- tetramethoxyxanthone, ) ;1,8-二羟基 - 2 ,3,6 -三甲氧基酮 (1,8- dihydroxy- 2 ,3,6 - trimethoxyxanthone, ) ;1-羟基 - 2 ,3,4 ,7-四甲氧基酮 (1- hydroxy- 2 ,3,4 ,7- te-tramethoxyxanthone, ) ;1,2 ,3,5 -四甲氧基酮 (1,2 ,3,5 - tetromethoxyxanthone, ) ;1-羟基 - 2 ,3,4 ,6 -四甲氧基酮 (1- hydroxyl- 2 ,3,4 ,6  相似文献   
4.
Interactions between the topoisomerase I inhibitor irinotecan (CPT-11) and the platinum derivative oxaliplatin (L-OHP) were investigated in HT29 colon cancer cell line. Synergism was observed when cells were simultaneously exposed to drugs or when cells were first exposed to CPT-11. Flow cytometric studies showed a G(2)/M accumulation when cells were exposed to the simultaneous and CPT-11-->L-OHP combinations whereas a persistent S phase delay was observed when cells were first exposed to L-OHP. We characterised the cytotoxic effect by assessing the induction of apoptosis. Irinotecan induced substantial DEVDase activity and poly(ADP-ribose) polymerase cleavage while this activity was moderate and delayed after exposure to L-OHP. Combination experiments showed a sequence-dependent onset of apoptosis, the CPT-11-->L-OHP schedule being the earliest and the most effective; on the other hand the apoptotic signaling generated by CPT-11 was partly inhibited in the simultaneous combination and in the L-OHP-->CPT-11 sequence. Cell death studies using a dual staining technique showed a shift from apoptosis to necrosis when combining these drugs at high concentrations. Synergistic interactions observed using CPT-11 before L-OHP may be linked to an early apoptotic signaling while the L-OHP-induced S phase block could account for the observed additive effect in the reverse sequence. An additional phenomenon might work towards synergism for the simultaneous combination.  相似文献   
5.
青叶胆酮类化合物的成分研究   总被引:1,自引:1,他引:1  
目的 分离鉴定青叶胆 Swertia mileensis全草的酮类成分。方法  95 %乙醇浸提 ,经硅胶柱色谱分离纯化 ,UV,IR,MS,1 H和 1 3CNMR波谱方法确定化学结构。结果 分得 12个酮成分 ,分别为 1-羟基 - 2 ,3,4 ,5 -四甲氧基酮 (1- hydroxy- 2 ,3,4 ,5 - tetramethoxyxanthone, ) ;1-羟基 - 2 ,3,7-三甲氧基酮 (1- hydroxy- 2 ,3,7-trim ethoxyxanthone, ) ;1-羟基 - 2 ,3,5 ,7-四甲氧基酮 (1- hydroxy- 2 ,3,5 ,7- tetram ethoxyxanthone, ) ;1,5 -二羟基 - 2 ,3-二甲氧基酮 (1,5 - dihydroxy- 2 ,3- dimethoxyxanthone, ) ;1,5 -二羟基 - 2 ,3,7-三甲氧基酮 (1,5 - dihy-droxy- 2 ,3,7- trimethoxyxanthone, ) ;1-羟基 - 2 ,3,5 -三甲氧基酮 (1- hydroxy- 2 ,3,5 - trimethoxyxanthone, ) ;1,5 -二羟基 - 2 ,3,4 ,7-四甲氧基酮 (1,5 - dihydroxy- 2 ,3,4 ,7- tetramethoxyxanthone, ) ;1,8-二羟基 - 2 ,3,6 -三甲氧基酮 (1,8- dihydroxy- 2 ,3,6 - trimethoxyxanthone, ) ;1-羟基 - 2 ,3,4 ,7-四甲氧基酮 (1- hydroxy- 2 ,3,4 ,7- te-tramethoxyxanthone, ) ;1,2 ,3,5 -四甲氧基酮 (1,2 ,3,5 - tetromethoxyxanthone, ) ;1-羟基 - 2 ,3,4 ,6 -四甲氧基酮 (1- hydroxyl- 2 ,3,4 ,6  相似文献   
6.
Geisthoff UW  Zenk J  Steinhart H  Iro H 《HNO》2001,49(3):194-198
BACKGROUND AND OBJECTIVE: A combined Ho:YAG/Nd:YAG laser produces light with properties similar to the beams of the mainly coagulating Nd:YAG laser and the cutting CO2 laser alone. PATIENTS/METHODS: The combined laser was tested in vitro on pig tissue. Additionally, we used this new combined tool for enoral operations. RESULTS: An effect of the pulsed Ho:YAG laser was explosive-like tissue disruption and sprinkling of fragments. Simultaneous use of the Nd:YAG laser resulted in an enlarged zone of coagulation. Clinically, the laser-assisted intervention was inferior to the classic operational methods. CONCLUSIONS: Comparing the established CO2 laser and the Ho:YAG laser, the latter showed only the advantage of delivery via a flexible fiber. Sprinkling of tissue fragments and wide incisions are oncologically problematic. We conclude that this new tool is of minor value for otorhinolaryngologists and head and neck surgeons.  相似文献   
7.
钬激光对兔肾脏实质的生物学效应   总被引:2,自引:1,他引:1  
目的探索钬激光用于治疗肾实质肿瘤的可行性.方法以兔子为试验对象,按完全随机的方式将兔子分组,每组接受不同参数(脉冲能量、频率、时间)的激光对双侧肾脏定点照射.通过肉眼观测、光镜观察及图像处理软件,观察钬激光对肾脏实质的气化、切割、凝固等生物学效应及范围.结果钬激光对肾实质具有气化、切割、凝固效应,同时有良好的止血效果,损伤带的直径随着激光的脉冲能量(F=767.104,P=0.000)、频率(F=3808.405,P=0.000)及照射时间(F=139.115,P=0.000)的增加而增大,差别均有统计学意义.钬激光功率与损伤直径有良好的相关性好(r=0.950,t=11.499,P=0.000),说明损伤的范围易于控制.切割带外围热损伤的宽度局限于0.4~0.8 mm,负损伤小.结论钬激光可以对肾组织产生精确的气化、切割、凝固效果,同时止血可靠,易于控制,可操作性强.可以用于肾实质肿瘤的治疗,可以在影像技术的引导下行穿刺介入治疗,或者通过腹腔镜下治疗,也可以在保肾手术中辅助切割.  相似文献   
8.
目的探讨经尿道输尿管镜钬激光肾盂内切开术治疗肾盂输尿管连接部狭窄的效果。方法2002年4月-2004年9月期间,经尿道输尿管镜下行肾盂内切开治疗成人型肾盂输尿管连接部狭窄30例。狭窄段纵行切开后,输尿管内放置8F双J管内引流,平均留置双J管6周,每间隔3个月行超声、排泄性尿路造影检查。结果术后随访3—22个月,平均18个月,22例临床症状缓解,影像学检查提示内切开段造影剂通过良好,治疗成功;8例手术失败,均为巨大肾盂积水患者,改行Aderson—Hynes离断性肾盂成形术治愈。结论经尿道输尿管镜下钬激光肾盂内切开术创伤小、安全有效,可做为轻中度肾盂积水肾盂输尿管连接部狭窄患者治疗的首选方法。  相似文献   
9.
10.

Background

Valganciclovir is widely used to prevent post-transplant cytomegalovirus (CMV) infection in kidney transplant patients. However, the currently used dose remains controversial because the continuous use of this drug decreases kidney function and can induce leukopenia.

Objective

The purpose of this study was to measure the appropriate dose of valganciclovir required to prevent CMV infection.

Methods

A systematic review and meta-analysis were performed by using a random effects model. The Cochrane Central Register, MEDLINE, EMBASE, and PubMed databases were searched up to April 15, 2017. We conducted analysis on low-dose (450 mg) and standard-dose (900 mg) valganciclovir groups.

Results

After completion of the research, the analysis revealed that the glomerular filtration rate, graft loss, tacrolimus level, antibody-mediated rejection, and fungal and Candida infection rates did not differ between the 2 groups. However, the incidence of CMV tended to decrease in the low-dose group (0.584 [95% confidence interval [CI], 0.352–0.967]; P = .036). The biopsy-proven rejection rate decreased by 0.427 times in the low-dose group compared with the standard-dose group (95% CI, 0.274–0.667; P = .002). Furthermore, the incidence of leukopenia decreased by 0.371 times in the low-dose group compared with the standard-dose group (95% CI, 0.264–0.523; P = .001).

Conclusions

The 450-mg dose of valganciclovir effectively prevented post-transplantation CMV infection and decreased drug-induced side effects such as leukopenia. In the future, the lower dose of valganciclovir should be considered to prevent CMV infection and enhance cost-effectiveness.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号